Establishing Endpoints - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Establishing Endpoints

Pharmaceutical Technology Europe
Volume 23, Issue 3

The unit selected for wet granulation, whether it be a high shear mixer or a fluidised bed, has a marked impact on granule properties. In routine operation, however, the desired outcomes are achieved by manipulating just a small number of operational variables. High shear mixing is the most widely used processing method and key operational variables include: the amount of granulation solution added, rate of addition, impeller speed and processing time.

Tim Freeman
Endpoint determination poses problems for two main reasons. Firstly, the granules manufactured are not usually the finished product and the manufacturer can only reliably assess granule quality by working them up, typically into a finished tablet. This means that the iterative process of changing granulation conditions — seeing whether the change is beneficial, and then making further changes — can be a lengthy one.

Secondly, granulation processes, as with other processes involving mixing, tend not to scale easily because conditions that produce good quality granulates in the lab are not necessarily optimal for pilot studies or commercial manufacture. At each new scale therefore, the optimal endpoint for the process must be re-established.

One traditional way for an experienced operator to detect endpoint is to open the granulator, manually extract a sample, compress it between their fingers and evaluate it by eye, but this is clearly a highly subjective technique!

A more scientific approach is to measure particle size. This can be successful where size is the defining characteristic of the granule; however, other parameters, such as shape or density, may also be important. Where this is the case, size measurement alone may be inadequate.

A common practice with commercial scale, high shear granulators is to monitor the power drawn by the impeller. As the granulation nears its endpoint, power consumption rises steeply because the granulating mass becomes denser, more adhesive and harder to move. With experience, the shape of the power consumption curve may become somewhat correlated with a defined endpoint, thus enabling its detection — although with varying degrees of accuracy.

Recent research has shown that Basic Flowability Energy (BFE) is a useful parameter with which to track wet granulation processes and define an endpoint. There are parallels here with monitoring the power drawn by the impeller because BFE is a measure of the energy required to maintain flow in a sample of powder or granulate. Measuring BFE, however, is far more precise because of the high reproducibility achievable with powder rheometry.

BFE is a dynamic powder property measured using a powder rheometer. As granulation proceeds, the powder properties remain relatively unchanged up to the transition point from wet mass to granules, a transition that essentially marks the end of the process. At this point, BFE rises sharply. Dense, stiff granules adhere more strongly to one another than the finer particles of the wet mass and so the bed begins to exert considerable resistance to flow. Because the rise in BFE is sharp, the parameter is sensitive to slight changes in the exact region of interest for endpoint detection, making it a precise measure for control.

Alternatively, it has also been shown that changes in permeability track the progression towards granules. As granulation proceeds and granules grow in size, permeability increases steadily. Because this parameter changes linearly with increasing water content, however, it is less sensitive than BFE for endpoint detection.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here